Advances in target treatment for non-small cell lung cancer

Chen Zhi-wei

2009-01-01

Abstract:肺癌是当今世界上对人类健康与生命危害最大的恶性肿瘤,其中非小细胞肺癌(NSCLC)占80%～85%,30%～40%的NSCLC在诊断时即属于晚期,失去了手术切除的机会[1].研究表明,含铂方案的化疗较最佳支持治疗能明显延长晚期NSCLC的生存[2-4].……

What problem does this paper attempt to address?

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

Chenyi Ren,He Cao,Jing Zheng,Wenjia Sun,Jianya Zhou

DOI: https://doi.org/10.3779/j.issn.1009-3419.2023.102.14

2023-01-01

Abstract:Lung cancer is the most common malignancy in the world and the leading cause of cancer death. Human epidermal growth factor receptor 2 (HER2) positive non-small cell lung cancer (NSCLC) refers to the NSCLC caused by mutation, amplification or overexpression of the HER2 gene, resulting in its dysfunction. HER2 is the most active receptor in the HER family and can combine with other members to form dimers, which can activate multiple signaling pathways and regulate cell proliferation, differentiation, migration and apoptosis. In NSCLC, HER2 positivity is usually considered a poor prognostic marker. At present, the diagnosis and treatment of HER2-positive NSCLC are not mature. Immunohistochemistry (IHC), next generation sequencing (NGS) and other technologies are often used to detect the positive status of HER2 mutation, amplification or overexpression. In previous studies, antitumor drugs did not show ideal therapeutic effects in HER2-positive NSCLC. However, in recent years, related researches have shown that antibody-drug conjugates (ADCs) and new tyrosine kinase inhibitors (TKIs) in targeted therapy show good antitumor activity against HER2 positive NSCLC. This article summarized the progress in diagnosis and treatment of HER2-positive NSCLC, so as to provide reference for subsequent researches. .
Medical Treatment of Advanced Non-Small Cell Lung Cancer: Progress in 2014

SONG Yong,YANG Wen

DOI: https://doi.org/10.11855/j.issn.0577-7402.2015.01.03

2015-01-01

Medical Journal of Chinese People's Liberation Army

Abstract:Non-small cell lung cancer is the most common pathological type of lung cancer. Along with the rising incidence in recent years, lung cancer has been the leading cause of death due to malignancies both in our country and worldwide. Due to simplistic therapeutic approach for lung cancer decades ago, those patients suffering from advanced lung cancer had short lifetime, and it was difficult to ensure their life quality. In recent years, many molecular targeted drugs, such as Gefitinib, Erlotinib and Crizotinib etc., have been successively applied in clinical use, and they bring about a substantial prolongation of survival life and improvement in life quality of those patients with advanced lung cancer. In 2014, there was a number of important reports concerning the diagnosis and treatment of non-small cell lung cancer in the annual meetings of either American Society of Clinical Oncology or European Society for Medical Oncology. On the basis of the relevant reports delivered in the conferences, it is our attempt to summarize the recent advances in regard to chemotherapy, molecular targeted therapy, measures to treat TKI therapy resistant cases, and immune therapy, followed by a comment regarding recent advances in the treatment of non-small cell lung cancer in 2014. DOI: 10.11855/j.issn.0577-7402.2015.01.03
Research status of targeted agents for the treatment of non-small cell lung cancer

Tan ZHANG,Yi-tong WANG,Yi FANG

DOI: https://doi.org/10.13699/j.cnki.1001-6821.2017.11.029

2017-01-01

Abstract:Objective Non-small cell lung cancer (NSCLC) occupied the most parts of the lung cancer with more than 85％ patients.And the clinical drug therapy had become the key point of the NSCLC in that the most patients of NSCLC were in middle or terminal stage as they are diagnosed.Now,the NSCLC patients can live longer than before with the help of development of targeted agents,besides,the drug therapy methods had enriched by individualized treatment concept.All these methods have brought the great gifts for the non-small cell lung cancer patients.This paper concludes the latest targeted agents for non-small lung cancer patients.
Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

TAN Fen-lai,WANG Yin-xiang,YUAN Xiao-fen,DING Lie-ming,HU Bei,ZHANG Li,ZHOU Jian-ying,SHENG-TU Jian-zhong,SUN Yan

2011-01-01

Abstract:Non-small cell lung cancer(NSCLC) is the leading cause of cancer mortality worldwide.The management of NSCLC has changed dramatically in the last decade.A number of well documented clinical studies demonstrated that the epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs) showed a better survival benefit comparing to the standard treatments in patients with advanced/metastatic NSCLC.EGFR-TKIs,including gefitinib and erlotinib,have been used in first-line,second-line and more other settings with obvious survival benefits in a subgroup of patients with EGFR mutations.Moreover,icotinib,a novel EGFR-TKIs developed by BetaPharma Inc.,has finished its phase III trial(ICOGEN) with encouraging efficacy and safety profile in China recently.This review will summarize the results of clinical trials of erlotinib,gefitinib or icotinib for patients with advanced NSCLC.
Combined targeted therapies of non-small cell lung cancer

Ming LI,Xiao-dong CHEN

DOI: https://doi.org/10.3760/cma.j.issn.1673-436X.2008.18.016

2008-01-01

Abstract:Non-small cell lung cancer(NSCLC) is a common malignant tumor. Majority of NSCLC patients can not be cured by traditional therapies, such as chemotherapy, radiotherapy or operations. Because most of them are in advanced stage when diagnosed. After a series of phase Ⅲ clinical trials,single targeted drugs have already been approbated to be used for patients. However, the effect can not meet expectation.With the study of pathogenesis of lung cancer and targeted drugs, combined targeted therapies would be a new choice.
Advance on Targeted Therapy for the Treatment of Non-Small Cell Lung Cancer

LI Zi-ming,LU Shun

DOI: https://doi.org/10.3760/cma.j.issn.1006-9801.2010.01.002

2010-01-01

Abstract:Recent progress in molecular biology has enabled us to better understand the molecular mechanism underlying pathogenesis of human malignancy including lung cancer, the advent of therapies based on mechanisms that target critical molecular pathways of tumors has evoked considerable interest. The therapeutic index is high, and optimally effective treatment can be achieved at a dose below the maximal tolerated dose,giving us a better understanding of the human lung cancer. This review focuses on the advance of targeted therapy for the first-line, second-line treatment or the maintenance treatment of non-small cell lung cancer.
Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer

Zhen-Xi Niu,Ya-Tao Wang,Nan Lu,Jin-Feng Sun,Peng Nie,Piet Herdewijn

DOI: https://doi.org/10.1016/j.ejmech.2023.115868

IF: 7.088

2023-10-15

European Journal of Medicinal Chemistry

Abstract:Lung cancer continues to pose a significant challenge as a prominent contributor to global cancer-related mortality. Despite the considerable strides made in therapeutic interventions within the past decade, a substantial population of patients diagnosed with non-small cell lung cancer (NSCLC) still face the grim reality of an incurable condition. In the realm of optimal management strategies for individuals afflicted with locally advanced, yet amenable to surgical resection, NSCLC, a therapeutic approach encompassing chemoradiation stands as a fundamental component. Significant strides have been made in the therapeutic landscape of NSCLC during the preceding two decades, facilitating an enhanced comprehension of the underlying disease biology, and mechanisms governing tumor progression, as well as advancements in early detection modalities and multimodal therapeutic interventions. Nevertheless, the overall rates of curative interventions and survival outcomes for NSCLC continue to exhibit a discouragingly low trajectory, particularly in the context of metastatic disease. Hence, the imperative for sustained research endeavors in the realm of novel pharmaceutical agents and combinatorial therapeutic approaches remains paramount, with the overarching objective of broadening the scope of clinical advantages conferred upon a wider demographic of patients, thereby fostering tangible improvements in outcomes pertaining to NSCLC. The primary objective of this review is to provide an all-encompassing examination encompassing the clinical application and synthetic routes of specific drugs, with the explicit aim of disseminating invaluable knowledge that can inform future research and development endeavors focused on NSCLC.

chemistry, medicinal
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Min Yuan,Li-Li Huang,Jian-Hua Chen,Jie Wu,Qing Xu

DOI: https://doi.org/10.1038/s41392-019-0099-9

IF: 39.3

2019-12-01

Signal Transduction and Targeted Therapy

Abstract:Abstract Lung cancer is one of the most common cancer in the world. In 2018, there were over 2 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient’s tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy.

biochemistry & molecular biology,cell biology
Targeted therapy drugs in non-small cell lung cancer

Hao WANG

DOI: https://doi.org/10.3760/cma.j.issn.1673-422X.2007.09.016

2007-01-01

Abstract:以吉非替尼(gefitinib)和埃罗替尼(erlotinib)为代表的小分子表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌是近年研究的热点,部分患者对药物反应良好,但几项大规模临床研究并没有得出这类药物可延长生存期的结论.研究表明,西妥昔单抗(cetuximab)和贝伐单抗(bevacizumab)等单克隆抗体可能提高患者的治疗反应率,延长生存期.不同人种、不同发病机制肿瘤的药物作用靶点不同,因此应根据临床状态、病理分型等影响因素指导患者接受个体化靶向药物治疗。
Medical treatment of non-small cell lung cancer:An update

Yong SONG,Jian-wei GAO

DOI: https://doi.org/10.16571/j.cnki.1008-8199.2017.11.001

2017-01-01

Abstract:Non-small cell lung cancer ( NSCLC) is the most common histological type and accounts for approximately 80%-85%of lung cancers , which can be classified into lung adenocarcinoma , squamous cell carcinomas , and so on.With the coming era of precise treatment, NSCLC is further divided into treatable oncogenic alterations negative-and positive-NSCLC.For patients without treatable oncogenic alterations , platinum-based chemotherapy remains the cornerstone of the treatment , and antiangiogenesis therapy al-so plays an important role in the subsequent treatment .For those with treatable oncogenic alterations , in addition to standard first gener-ation EGFR-TKIs and ALK-TKIs, second and third generation targeted drugs have been investigated in first line or post -resistance treat-ment.The application of immune checkpoint inhibitors has become a new trend of lung cancer treatment .Our review summarizes recent advances in chemotherapy , antiangiogenesis therapy ,target therapy , and immunotherapyof NSCLC .
Breakthrough in targeted therapy for non-small cell lung cancer

Zhencong Ye,Yongmei Huang,Jianhao Ke,Xiao Zhu,Shuilong Leng,Hui Luo

DOI: https://doi.org/10.1016/j.biopha.2020.111079

Abstract:Non-small cell lung cancer (NSCLC) remains by far the single most common malignancy of lung cancer which causes more and more mortality in recent years. NSCLC accounts for more than 80 % of lung cancers, and the vast majority of patients were found to be in advanced inoperable stages. Chemotherapy used to be the main treatment for NSCLC, but due to its obvious side effects. Chemotherapy gradually withdrew from the stage of history. In recent years, cellular and molecular biotechnology has developed rapidly, and researchers have begun to target key genes and regulatory molecules for treatment. Targeted drugs have also emerged. The purpose of this review is to introduce important research achievements in recent years and the treatment progress of new drugs.
Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Yuan Cheng,Tao Zhang,Qing Xu

DOI: https://doi.org/10.1002/mco2.105

2021-12-01

MedComm

Abstract:Lung cancer still contributes to nearly one-quarter cancer-related deaths in the past decades, despite the rapid development of targeted therapy and immunotherapy in non-small cell lung cancer (NSCLC). The development and availability of comprehensive genomic profiling make the classification of NSCLC more precise and personalized. Most treatment decisions of advanced-stage NSCLC have been made based on the genetic features and PD-L1 expression of patients. For the past 2 years, more than 10 therapeutic strategies have been approved as first-line treatment for certain subgroups of NSCLC. However, some major challenges remain, including drug resistance and low rate of overall survival. Therefore, we discuss and review the therapeutic strategies of NSCLC, and focus on the development of targeted therapy and immunotherapy in advanced-stage NSCLC. Based on the latest guidelines, we provide an updated summary on the standard treatment for NSCLC. At last, we discussed several potential therapies for NSCLC. The development of new drugs and combination therapies both provide promising therapeutic effects on NSCLC.
Recent progress in targeted therapy for non-small cell lung cancer

Yajun Lin,Yanxia Xiao,Pu Liu,Jie Wei,Xin Zhang,Jun Guo

DOI: https://doi.org/10.3389/fphar.2023.1125547

IF: 5.6

2023-02-22

Frontiers in Pharmacology

Abstract:The high morbidity and mortality of non-small cell lung cancer (NSCLC) have always been major threats to people's health. With the identification of carcinogenic drivers in non-small cell lung cancer and the clinical application of targeted drugs, the prognosis of non-small cell lung cancer patients has greatly improved. However, in a large number of non-small cell lung cancer cases, the carcinogenic driver is unknown. Identifying genetic alterations is critical for effective individualized therapy in NSCLC. Moreover, targeted drugs are difficult to apply in the clinic. Cancer drug resistance is an unavoidable obstacle limiting the efficacy and application of targeted drugs. This review describes the mechanisms of targeted-drug resistance and newly identified non-small cell lung cancer targets (e.g., KRAS G12C, NGRs, DDRs, CLIP1-LTK, PELP1, STK11/LKB1, NFE2L2/KEAP1, RICTOR, PTEN, RASGRF1, LINE-1, and SphK1). Research into these mechanisms and targets will drive individualized treatment of non-small cell lung cancer to generate better outcomes.

pharmacology & pharmacy
New Trends of Advanced Non-Small Cell Lung Cancer Therapy

石远凯,郏博

2012-01-01

Abstract:Developing new molecular targeted drugs according to driver genes that are associated with tumor genesis and development has become the focus in lung cancer researches.Significant progress has been achieved in multiple therapy methods such as targeted agents,novel chemotherapeutic drugs,angiogenesis inhibitors and therapeutic vaccines.Epidermal growth factor receptor tyrosine kinase inhibition(EGFR-TKI) is associated with better survival compared with traditional chemotherapy for NSCLC patients.S-1 will be a new option for advanced NSCLC patients,and crizotinib has become the standard therapy for EML4-ALK positive NSCLC patients.Angiogenesis inhibitors and therapeutic vaccines have been developed rapidly.These results will change the current therapy strategy for NSCLC patients,and individualized therapy according to clinical characteristic and molecular subtype will be the new trend.
Advances in the Treatment for Non-small Cell Lung Cancer with Solitary Metastasis

段建春,王洁

DOI: https://doi.org/10.3969/j.issn.1000-8179.2009.20.017

2009-01-01

Chinese Journal of Clinical Oncology

Abstract:Lung cancer is one of the most common tumors which are threatening human lives. About 40% of non-small cell lung cancer (NSCLC) patients were diagnosed at stage Ⅳ. Among these patients, a few presented with early-stage primary lesion accompanied with solitary metastasis in single organ. The management and prognosis of these patients are different from those of patients diagnosed with multiple metastases. For NSCLC with solitary brain metastasis, if the primary tumor has been resected completely or controlled properly, synchronous or heterochronous resection of the solitary brain metastatic focus will raise the 5-year survival rate to 10%-30%. Presently, radical resection of primary and cerebral metastatic tumor or stereotactic radiation combined with whole brain radiotherapy is recommended for such patients. The morbility of solitary adrenal gland metastasis in NSCLC is about 1.62%～3.5%. Radical resection of primary and metastatic tumors combined with chemotherapy could prolong survival of these patients. The 5-year survival rate for these patients could reach 25%～40%. In conclusion, radical resection of the primary and metastatic tumors could prolong the survival of NSCLC patients with solitary metastasis in the brain or adrenal gland or other sites.
Research Progress and Clinical Application of Targeting Medicines in the Treatment Against Non-Small Cell Lung Cancer

CHEN Xiao-dong

2010-01-01

Abstract:Molecular targeting therapy has became a new approach in the treatment of advanced non-small cell lung cancer(NSCLC).The targeting medicines for NSCLC focus on epidermal growth factor receptor(EGFR) and vascular endothelial growth factor(VEGF).Multi-targeting drugs and combined approaches are reviewed in this paper.
Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives

Joan Minguet,Katherine H Smith,Peter Bramlage

DOI: https://doi.org/10.1002/ijc.29915

2016-06-01

Abstract:Non-small cell lung cancer (NSCLC) is one of the most deadly cancers worldwide, with poor prognosis once the disease has progressed past the point at which surgery is a viable option. Whilst chemotherapy has improved survival over recent decades, there is still great need for improvements in treatments for patients with advanced disease. Over the last decade, a variety of such drugs have received market approval for treating NSCLC, with a variety of others in the pipeline. Here, we review the development of targeted therapies for the treatment of advanced or metastatic NSCLC, including those already in clinical practice and those in early trials. The epidermal growth factor receptor (EGFR) inhibitors, gefitinib, erlotinib and afatinib; the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib; and the anti-vascular endothelial growth factor receptor monoclonal antibody, bevacizumab, are already providing improved survival for patients with NSCLC. Moreover, the discovery of EGFR mutations and ALK rearrangements has enabled the identification of patients who are more likely to benefit from a specific drug. The recent approval of the immune checkpoint inhibitor nivolumab, along with the designation of alectinib and MPDL3280A as breakthrough therapies by the FDA, demonstrates how rapidly this area of research is expanding. Over the last decade there has been significant progress made in the treatment of advanced NSCLC, and the large and varied selection of drugs currently undergoing trials provide great promise for improving the prognosis of this highly prevalent and deadly form of cancer.
Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials

Le Yu,Ruoyi Yang,Zeng Long,Qingxiu Tao,Bin Liu

DOI: https://doi.org/10.3389/fonc.2024.1451230

IF: 4.7

2024-09-27

Frontiers in Oncology

Abstract:Lung cancer is a leading cause of cancer-related deaths globally, and traditional chemotherapy has limited efficacy in treating advanced non-small cell lung cancer (NSCLC). In recent years, the prognosis for patients with NSCLC has significantly improved due to the development of new treatment modalities, including targeted therapies. Targeted therapies utilize monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), or small molecule tyrosine kinase inhibitors (TKIs) directed against specific mutated genes such as EGFR and ALK. The development of these drugs has deepened our understanding of NSCLC and improved treatment outcomes for patients. This review aims to summarize the mechanisms and current status of targeted therapy for NSCLC, discuss strategies to overcome acquired resistance, and address current challenges in the field.

oncology
Chinese Expert Consensus on Molecularly Targeted Therapy for Advanced Non-Small Cell Lung Cancer (2013 Edition).

Guoming Wu,Caicun Zhou,Chunxue Bai,Guisheng Qian

DOI: https://doi.org/10.3978/j.issn.2072-1439.2014.09.20

2014-01-01

Abstract:Lung cancer is one of the most common malignant tumors worldwide, ranking the first of all cancers in terms of mortality. More than 80-85% lung cancers are non-small cell lung cancer (NSCLC), and most of them are in advanced stages at the time of diagnosis (1). Although the role of chemotherapy for NSCLC remains virtually unchanged in recent years, the therapeutic efficacy has reached a plateau. Moreover, toxic and adverse reactions have limited its further clinical applications. Instead, targeted therapy has aroused the widest attention and become one of the most promising therapeutic strategies owing to the reliable therapeutic effect, low toxicity and mild adverse reactions (2). The expert panels from the Respiratory Disease Branch Lung Cancer Study Group of the Chinese Medical Association and the Chinese Alliance Against Lung Cancer have discussed issues related to molecularly targeted treatments for advanced NSCLC and reached consensus on molecularly targeted treatments for advanced NSCLC (2013 edition) in the contest of the national conditions in Mainland China.
Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments

Jianan Xu,Lin Tian,Wenlong Qi,Qingguo Lv,Tan Wang

DOI: https://doi.org/10.1097/COC.0000000000001088

2024-06-01

Abstract:With the global incidence of non-small cell lung cancer (NSCLC) on the rise, the development of innovative treatment strategies is increasingly vital. This review underscores the pivotal role of precision medicine in transforming NSCLC management, particularly through the integration of genomic and epigenomic insights to enhance treatment outcomes for patients. We focus on the identification of key gene mutations and examine the evolution and impact of targeted therapies. These therapies have shown encouraging results in improving survival rates and quality of life. Despite numerous gene mutations being identified in association with NSCLC, targeted treatments are available for only a select few. This paper offers an exhaustive analysis of the pathogenesis of NSCLC and reviews the latest advancements in targeted therapeutic approaches. It emphasizes the ongoing necessity for research and development in this domain. In addition, we discuss the current challenges faced in the clinical application of these therapies and the potential directions for future research, including the identification of novel targets and the development of new treatment modalities.

Advances in target treatment for non-small cell lung cancer

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

Medical Treatment of Advanced Non-Small Cell Lung Cancer: Progress in 2014

Research status of targeted agents for the treatment of non-small cell lung cancer

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

Combined targeted therapies of non-small cell lung cancer

Advance on Targeted Therapy for the Treatment of Non-Small Cell Lung Cancer

Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Targeted therapy drugs in non-small cell lung cancer

Medical treatment of non-small cell lung cancer:An update

Breakthrough in targeted therapy for non-small cell lung cancer

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Recent progress in targeted therapy for non-small cell lung cancer

New Trends of Advanced Non-Small Cell Lung Cancer Therapy

Advances in the Treatment for Non-small Cell Lung Cancer with Solitary Metastasis

Research Progress and Clinical Application of Targeting Medicines in the Treatment Against Non-Small Cell Lung Cancer

Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives

Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials

Chinese Expert Consensus on Molecularly Targeted Therapy for Advanced Non-Small Cell Lung Cancer (2013 Edition).

Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments